Annual Cash & Cash Equivalents
$137.33 M
+$28.36 M+26.03%
December 31, 2023
Summary
- As of February 7, 2025, RVNC annual cash & cash equivalents is $137.33 million, with the most recent change of +$28.36 million (+26.03%) on December 31, 2023.
- During the last 3 years, RVNC annual cash & cash equivalents has fallen by -$196.23 million (-58.83%).
- RVNC annual cash & cash equivalents is now -58.83% below its all-time high of $333.56 million, reached on December 31, 2020.
Performance
RVNC Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$58.59 M
-$22.87 M-28.08%
September 30, 2024
Summary
- As of February 7, 2025, RVNC quarterly cash and cash equivalents is $58.59 million, with the most recent change of -$22.87 million (-28.08%) on September 30, 2024.
- Over the past year, RVNC quarterly cash and cash equivalents has dropped by -$120.73 million (-67.33%).
- RVNC quarterly cash and cash equivalents is now -83.88% below its all-time high of $363.51 million, reached on June 30, 2020.
Performance
RVNC Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RVNC Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +26.0% | -67.3% |
| 3 y3 years | -58.8% | -53.9% |
| 5 y5 years | +87.5% | -0.6% |
RVNC Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +26.0% | -70.5% | at low |
| 5 y | 5-year | -58.8% | +26.0% | -83.9% | at low |
| alltime | all time | -58.8% | +3408.7% | -83.9% | +2968.9% |
Revance Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $58.59 M(-28.1%) |
| Jun 2024 | - | $81.45 M(-38.6%) |
| Mar 2024 | - | $132.61 M(-3.4%) |
| Dec 2023 | $137.33 M(+26.0%) | $137.33 M(-23.4%) |
| Sep 2023 | - | $179.32 M(+27.0%) |
| Jun 2023 | - | $141.24 M(+3.3%) |
| Mar 2023 | - | $136.68 M(+25.4%) |
| Dec 2022 | $108.97 M(-1.5%) | $108.97 M(+4.3%) |
| Sep 2022 | - | $104.49 M(+50.5%) |
| Jun 2022 | - | $69.42 M(-65.0%) |
| Mar 2022 | - | $198.36 M(+79.3%) |
| Dec 2021 | $110.62 M(-66.8%) | $110.62 M(-13.0%) |
| Sep 2021 | - | $127.18 M(-24.1%) |
| Jun 2021 | - | $167.63 M(-32.8%) |
| Mar 2021 | - | $249.43 M(-25.2%) |
| Dec 2020 | $333.56 M(+94.9%) | $333.56 M(-1.7%) |
| Sep 2020 | - | $339.44 M(-6.6%) |
| Jun 2020 | - | $363.51 M(+26.8%) |
| Mar 2020 | - | $286.65 M(+67.5%) |
| Dec 2019 | $171.16 M(+133.6%) | $171.16 M(+190.5%) |
| Sep 2019 | - | $58.92 M(-34.6%) |
| Jun 2019 | - | $90.03 M(+37.9%) |
| Mar 2019 | - | $65.27 M(-10.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $73.26 M(-74.1%) | $73.26 M(+62.3%) |
| Sep 2018 | - | $45.13 M(+14.9%) |
| Jun 2018 | - | $39.28 M(-43.2%) |
| Mar 2018 | - | $69.21 M(-75.5%) |
| Dec 2017 | $282.90 M(+345.5%) | $282.90 M(+402.3%) |
| Sep 2017 | - | $56.32 M(+4.9%) |
| Jun 2017 | - | $53.69 M(+40.4%) |
| Mar 2017 | - | $38.23 M(-39.8%) |
| Dec 2016 | $63.50 M(-68.5%) | $63.50 M(-51.3%) |
| Sep 2016 | - | $130.48 M(+147.8%) |
| Jun 2016 | - | $52.65 M(+29.1%) |
| Mar 2016 | - | $40.79 M(-79.8%) |
| Dec 2015 | $201.62 M(+17.9%) | $201.62 M(+122.8%) |
| Sep 2015 | - | $90.49 M(-6.1%) |
| Jun 2015 | - | $96.42 M(-37.3%) |
| Mar 2015 | - | $153.72 M(-10.1%) |
| Dec 2014 | $171.03 M(+4269.7%) | $171.03 M(-8.8%) |
| Sep 2014 | - | $187.49 M(-7.8%) |
| Jun 2014 | - | $203.31 M(+131.4%) |
| Mar 2014 | - | $87.85 M(+2144.6%) |
| Dec 2013 | $3.91 M(-4.1%) | $3.91 M(+105.0%) |
| Sep 2013 | - | $1.91 M(-53.2%) |
| Dec 2012 | $4.08 M(-86.2%) | $4.08 M |
| Dec 2011 | $29.62 M | - |
FAQ
- What is Revance Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Revance Therapeutics?
- What is Revance Therapeutics annual cash & cash equivalents year-on-year change?
- What is Revance Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Revance Therapeutics?
- What is Revance Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Revance Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of RVNC is $137.33 M
What is the all time high annual cash & cash equivalents for Revance Therapeutics?
Revance Therapeutics all-time high annual cash & cash equivalents is $333.56 M
What is Revance Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, RVNC annual cash & cash equivalents has changed by +$28.36 M (+26.03%)
What is Revance Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RVNC is $58.59 M
What is the all time high quarterly cash and cash equivalents for Revance Therapeutics?
Revance Therapeutics all-time high quarterly cash and cash equivalents is $363.51 M
What is Revance Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, RVNC quarterly cash and cash equivalents has changed by -$120.73 M (-67.33%)